Product image of Metformina + Sitagliptina Ratiopharm Ratiopharm (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Ratiopharm Ratiopharm

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Ratiopharm Ratiopharm (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina Ratiopharm, is a biguanide presented as a tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet and exercise.

GNH India supplies Metformina + Sitagliptina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Manufacturer / TM Owner

Ratiopharm-Comercio E Industria De Produtos Farmaceuticos Lda

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina is an oral antidiabetic combination that targets hyperglycemia in type 2 diabetes.

  • Type 2 diabetes mellitus: improves blood glucose control as an adjunct to diet and exercise.
  • Metformin‑intolerant patients: offers an additional glucose‑lowering mechanism when metformin dose is limited.
  • Inadequate control on metformin monotherapy: adds DPP‑4 inhibition to enhance insulin secretion and reduce glucagon.

How It Works

  • Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby lowering fasting glucose production. Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The combined effect enhances glucose‑dependent insulin release, suppresses glucagon secretion, and improves overall glycemic control without causing hypoglycemia when used alone and supports better post‑prandial glucose regulation.

Side Effects

Metformina + Sitagliptina may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Upper respiratory symptoms: nasopharyngitis or cough.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic complication.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe hypersensitivity: skin rash, angioedema, or anaphylaxis.

Precautions & Warnings

When prescribing Metformina + Sitagliptina, clinicians should observe several precautionary measures to minimise risk.

  • Renal function assessment: evaluate eGFR before initiation and periodically thereafter.
  • Hepatic impairment: avoid use in patients with significant liver disease due to lactic acidosis risk.
  • Lactic acidosis risk: discontinue if patient develops severe infection, dehydration, or hypoxia.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
  • Concomitant alcohol use: limit intake to reduce lactic acidosis potential.
  • Store at room temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Metformina + Sitagliptina can interact with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

  • Iodinated contrast agents: risk of renal impairment and lactic acidosis; withhold metformin around the procedure.
  • Cimetidine: may increase metformin plasma concentrations.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin levels.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal function and metformin clearance.
  • NSAIDs: can impair renal function, increasing metformin accumulation.
  • Alcohol: enhances risk of lactic acidosis.

Frequently Asked Questions

Metformina + Sitagliptina is indicated for the treatment of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycaemic control when monotherapy with either component is insufficient.

Metformin lowers hepatic glucose production and increases insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, prolonging the action of incretin hormones that stimulate insulin release and suppress glucagon. The combined actions provide complementary glucose‑lowering effects.

The dosage is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the dosing instructions provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless specifically advised by a physician.

Enquiries can be submitted on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with separate metformin or sitagliptin tablets, the fixed‑dose combination simplifies the regimen and may improve adherence. Unlike sulfonylureas, it has a lower intrinsic risk of hypoglycaemia, and unlike insulin, it is administered orally.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water and do not crush or chew it unless specifically instructed.

The most serious adverse events include lactic acidosis, which can be fatal, and acute pancreatitis. Severe hypersensitivity reactions such as anaphylaxis may also occur. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

The combination is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hepatic disease, a history of lactic acidosis, or hypersensitivity to either component. It should also be avoided in pregnant women unless clearly indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT